Evidence map›Paper›PMID 28192475›Full record

ArticlePloS one2017

Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.

Louise M Burrell, Daniel Gayed, Karen Griggs, Sheila K Patel, Elena Velkoska

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. The renin-angiotensin system in models of pulmonary arterial hypertension vs primary hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Review
  7. An update on ACE2 amplification and its therapeutic potential.Acta physiologica (Oxford, England) · 2021
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Louise M BurrellDepartment of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
Daniel GayedDepartment of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
Karen GriggsDepartment of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
Sheila K PatelDepartment of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
Elena VelkoskaDepartment of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.ORCID http://orcid.org/0000-0002-7946-0944
The University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported that exogenous angiotensin (Ang) 1-7 has adverse cardiac effects in experimental kidney failure due to its action to increase cardiac angiotensin converting enzyme (ACE) activity. This study investigated if the addition of an ACE inhibitor (ACEi) to Ang 1-7 infusion would unmask any beneficial effects of Ang 1-7 on the heart in experimental kidney failure. Male Sprague-Dawley rats underwent subtotal nephrectomy (STNx) and were treated with vehicle, the ACEi ramipril (oral 1mg/kg/day), Ang 1-7 (subcutaneous 24 μg/kg/h) or dual therapy (all groups, n = 12). A control group (n = 10) of sham-operated rats were also studied. STNx led to hypertension, renal impairment, cardiac hypertrophy and fibrosis, and increased both left ventricular ACE2 activity and ACE binding. STNx was not associated with changes in plasma levels of ACE, ACE2 or angiotensin peptides. Ramipril reduced blood pressure, improved cardiac hypertrophy and fibrosis and inhibited cardiac ACE. Ang 1-7 infusion increased blood pressure, cardiac interstitial fibrosis and cardiac ACE binding compared to untreated STNx rats. Although in STNx rats, the addition of ACEi to Ang 1-7 prevented any deleterious cardiac effects of Ang 1-7, a limitation of the study is that the large increase in plasma Ang 1-7 with ramipril may have masked any effect of infused Ang 1-7.

Indexed as

Analysis of VarianceAngiotensin-Converting Enzyme InhibitorsAngiotensin IAnimalsBlood PressureCardiomegalyHeartHypertensionMaleMyocardiumNephrectomyPeptide FragmentsPeptidyl-Dipeptidase ARamiprilRats, Sprague-DawleyRenal InsufficiencyAngiotensin-Converting Enzyme InhibitorsAngiotensin Iangiotensin I (1-7)Peptide FragmentsPeptidyl-Dipeptidase ARamipril

Identifiers

PMID28192475
PMCPMC5305254
OpenAlexW2588825806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.